INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
INCYTE CORP
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$113.25+0.18 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $23.42B
- P/E (TTM)
- 16.0
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
203M of 203M shares
Institutional holders
858
125 new, 71 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 46 sales
Net sold $57.96M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| State Street Corporation | 9,677,414 | 5.00% | 13G (passive) | Sep 30, 2025 |
| Felix J. Baker | 31,225,572 | 15.60% | 13D (active) amendment | May 7, 2026 |
| BlackRock, Inc. | 15,242,171 | 7.80% | 13G (passive) amendment | Sep 30, 2025 |
| Vanguard Capital Management | 12,591,630 | 6.32% | 13G (passive) | Mar 31, 2026 |
| Dodge & Cox | 12,252,356 | 6.20% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INCY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 30,762,330 | 15.18% | $3.49B | +17,918 | 17.48% |
| BlackRock, Inc. | 18,032,718 | 8.90% | $2.04B | −945,480 | 0.03% |
| Dodge & Cox | 11,957,326 | 5.90% | $1.36B | −295,030 | 0.71% |
| Vanguard Capital Management LLC | 11,024,289 | 5.44% | $1.25B | +94,223 | 0.03% |
| State Street Corp | 9,722,336 | 4.80% | $1.10B | +80,952 | 0.03% |
| Vanguard Portfolio Management LLC | 7,791,091 | 3.84% | $883.20M | +31,908 | 0.04% |
| Aqr Capital Management LLC | 5,320,901 | 2.63% | $603.18M | −487,029 | 0.21% |
| Geode Capital Management, LLC | 4,750,735 | 2.34% | $536.52M | +47,551 | 0.03% |
| Lsv Asset Management | 4,123,759 | 2.03% | $467.47K | +203,703 | 0.85% |
| Invesco Ltd. | 4,080,461 | 2.01% | $462.56M | +209,697 | 0.04% |
| Wellington Management Group Llp | 3,575,521 | 1.76% | $405.32M | +309,385 | 0.07% |
| Renaissance Technologies LLC | 3,512,132 | 1.73% | $398.14M | −139,400 | 0.55% |
| Morgan Stanley | 2,948,364 | 1.45% | $334.23M | +98,036 | 0.02% |
| Arrowstreet Capital, Limited Partnership | 2,744,958 | 1.35% | $311.17M | −85,841 | 0.14% |
| Robeco Institutional Asset Management B.V. | 2,441,735 | 1.20% | $276.80M | −72,648 | 0.34% |
| Goldman Sachs Group Inc | 2,305,782 | 1.14% | $261.38M | −45,439 | 0.02% |
| Dimensional Fund Advisors LP | 2,280,803 | 1.13% | $258.59M | +305,259 | 0.05% |
| Two Sigma Investments, LP | 2,003,559 | 0.99% | $227.12M | +1,587,645 | 0.16% |
| Northern Trust Corp | 1,761,966 | 0.87% | $199.74M | −87,760 | 0.02% |
| Charles Schwab Investment Management Inc | 1,692,439 | 0.83% | $191.85M | −36,663 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 858 | 203M | 100.0% | 125 / 363 | 272 / 71 | 11M | 12M |
| Q1 2026 | 815 | 204M | 100.0% | 109 / 320 | 289 / 104 | 35M | 12M |
| Q4 2025 | 822 | 202M | 99.4% | 175 / 336 | 234 / 49 | 18M | 13M |
| Q3 2025 | 713 | 199M | 98.1% | 126 / 264 | 234 / 63 | 17M | 15M |
| Q2 2025 | 658 | 197M | 97.3% | 101 / 263 | 235 / 63 | 19M | 11M |
| Q1 2025 | 628 | 190M | 93.7% | 73 / 258 | 222 / 83 | 19M | 11M |
| Q4 2024 | 650 | 183M | 90.4% | 125 / 243 | 213 / 57 | 15M | 16M |
| Q3 2024 | 593 | 184M | 91.0% | 83 / 171 | 263 / 69 | 30M | 22M |
| Q2 2024 | 584 | 198M | 97.8% | 73 / 226 | 221 / 68 | 19M | 44M |
| Q1 2024 | 586 | 224M | 100.0% | 88 / 216 | 203 / 52 | 15M | 13M |
| Q4 2023 | 557 | 223M | 100.0% | 98 / 197 | 197 / 61 | 24M | 14M |
| Q3 2023 | 529 | 212M | 100.0% | 51 / 249 | 164 / 47 | 18M | 13M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of INCY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Dodge & Cox Stock Fund | 7,953,128 | 3.92% | $901.57M | 0.76% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 5,390,922 | 2.66% | $611.11M | 0.03% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 4,346,927 | 2.14% | $492.77M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,894,319 | 1.92% | $441.46M | 0.23% | Jun 30, 2026 |
| Vanguard Health Care Fund | 2,386,201 | 1.18% | $285.20M | 0.75% | Jul 31, 2026 |
| iShares Core S&P 500 ETF | 2,309,810 | 1.14% | $261.84M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 2,245,641 | 1.11% | $254.57M | 0.54% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 2,139,308 | 1.06% | $206.96M | 0.02% | May 31, 2026 |
| Invesco S&P 500 Equal Weight ETF | 1,767,886 | 0.87% | $211.30M | 0.22% | Jul 31, 2026 |
| iShares Biotechnology ETF | 1,402,629 | 0.69% | $159.00M | 1.75% | Jun 30, 2026 |
| VictoryShares Free Cash Flow ETF | 1,191,786 | 0.59% | $135.10M | 1.74% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,185,538 | 0.58% | $134.39M | 0.33% | Jun 30, 2026 |
| Dodge & Cox Balanced Fund | 1,126,600 | 0.56% | $127.71M | 0.87% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 944,922 | 0.47% | $107.12M | 1.00% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 910,423 | 0.45% | $103.21M | 0.03% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William Meury | Chief Executive Officer, Director | 183,129 | 0.09% | Jul 20, 2026 |
| David H. Gardner | EVP, Chief Strategy Officer | 15,904 | 0.01% | Sep 24, 2026 |
| Pablo J. Cagnoni | President, Global Head of R&D | 186,157 | 0.09% | Sep 17, 2026 |
| Ramitpal K. Basi | EVP, Human Resources | 10,993 | 0.01% | Aug 27, 2026 |
| Patrick A. Mayes | EVP & Chief Scientific Officer | 63,648 | 0.03% | Aug 7, 2026 |
| Lee Heeson | EVP, Head of Incyte Intl | 38,041 | 0.02% | Jul 27, 2026 |
| Michael James Morrissey | EVP, Head of Tech. Operations | 34,065 | 0.02% | Jul 27, 2026 |
| Thomas Tray | Principal Accounting Officer | 23,098 | 0.01% | Jul 20, 2026 |
| Richard A. Hoffman | EVP & General Counsel | 16,861 | 0.01% | Jul 20, 2026 |
| Steven H. Stein | CMO & Head of Late-Stage Dev. | 30,916 | 0.02% | Jul 20, 2026 |
| Mohamed Khairie Issa | EVP, Head of U.S. Commercial | 63,940 | 0.03% | Jul 20, 2026 |
| Suketu Upadhyay | EVP & Chief Financial Officer | 26,343 | 0.01% | May 6, 2026 |
| Matteo Trotta | EVP, GM, Dermatology US | 14,882 | 0.01% | Mar 26, 2026 |
| Sheila A. Denton | EVP & General Counsel | 26,569 | 0.01% | Nov 19, 2025 |
| Vijay K. Iyengar | EVP, GMAPPS | 40,540 | 0.02% | Jul 17, 2025 |
| Barry P. Flannelly | EVP & General Manager US | 35,149 | 0.02% | Jul 17, 2025 |
| Paula J. Swain | EVP, Human Resources | 106,482 | 0.05% | Jul 16, 2025 |
| Christiana Stamoulis | EVP & Chief Financial Officer | 125,759 | 0.06% | Jul 16, 2025 |
| Edmund Harrigan | Director | 23,019 | 0.01% | Jul 2, 2026 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 28,497,742 | 14.06% | Jul 2, 2026 |
| Bros. Advisors Lp Baker | Director, 10% owner | 3,146,864 | 1.55% | Jul 2, 2026 |
| 667, L.P. | Director, 10% owner | 3,132,639 | 1.55% | Jul 2, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | 28,502,181 | 14.06% | Jul 2, 2026 |
| Felix Baker | Director, 10% owner | 28,517,943 | 14.07% | Jul 2, 2026 |
| Julian Baker | Director, 10% owner | 33,757,526 | 16.65% | Jul 2, 2026 |
| Paul J. Clancy | Director | 25,635 | 0.01% | Jul 2, 2026 |
| Jacqualyn A. Fouse | Director | 20,968 | 0.01% | Jun 10, 2026 |
| Jean Jacques Bienaime | Director | 24,424 | 0.01% | Jun 10, 2026 |
| Katherine A. High | Director | 14,983 | 0.01% | Jun 10, 2026 |
| Otis W. Brawley | Director | 12,894 | 0.01% | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David H. Gardner EVP, Chief Strategy Officer | Sep 22, 2026 | Tax withholding | −920 | $126.93 | $116.78K | 15,904 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Option exercise | +2,957 | $61.76 | $182.62K | 186,157 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Option exercise | +4,551 | $61.18 | $278.43K | 190,708 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Option exercise | +6,477 | $64.25 | $416.15K | 197,185 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Option exercise | +9,233 | $71.93 | $664.13K | 206,418 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Sale(10b5-1 plan) | −13,985 | $120.49 | $1.69M | 183,200 |
| Pablo J. Cagnoni President, Global Head of R&D | Sep 15, 2026 | Sale(10b5-1 plan) | −9,233 | $120.50 | $1.11M | 197,185 |
| Ramitpal K. Basi EVP, Human Resources | Aug 25, 2026 | Tax withholding | −504 | $129.72 | $65.38K | 10,993 |
| Pablo J. Cagnoni President, Global Head of R&D | Aug 19, 2026 | Sale(10b5-1 plan) | −10,801 | $125.56 | $1.36M | 183,200 |
| Pablo J. Cagnoni President, Global Head of R&D | Aug 12, 2026 | Sale(10b5-1 plan) | −10,803 | $120.04 | $1.30M | 194,001 |
| Pablo J. Cagnoni President, Global Head of R&D | Aug 5, 2026 | Sale(10b5-1 plan) | −10,640 | $122.69 | $1.31M | 204,804 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Aug 5, 2026 | Option exercise | +2,207 | $106.47 | $234.98K | 63,648 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Aug 5, 2026 | Sale(10b5-1 plan) | −2,207 | $123.99 | $273.65K | 61,441 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −6,055 | $120.43 | $729.20K | 61,441 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Aug 3, 2026 | Option exercise | +6,055 | $105.43 | $638.38K | 67,496 |
| Pablo J. Cagnoni President, Global Head of R&D | Jul 31, 2026 | Sale(10b5-1 plan) | −15,888 | $119.70 | $1.90M | 215,444 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +3,148 | $68.62 | $216.02K | 74,687 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,709 | $61.76 | $167.31K | 71,539 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,284 | $64.25 | $146.75K | 68,830 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,918 | $61.18 | $178.52K | 66,546 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −2,293 | $119.41 | $273.81K | 61,441 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −326 | $121.69 | $39.67K | 63,734 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −85 | $122.19 | $10.39K | 64,060 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −1,642 | $119.38 | $196.02K | 64,145 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −1,643 | $119.51 | $196.35K | 65,787 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −2,864 | $119.40 | $341.96K | 67,430 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −6,171 | $119.43 | $737.00K | 74,989 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −2,187 | $119.47 | $261.28K | 81,160 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −5,332 | $119.42 | $636.75K | 83,347 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −14,661 | $119.46 | $1.75M | 88,679 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +326 | $105.43 | $34.37K | 103,340 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +85 | $106.47 | $9.05K | 103,014 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,293 | $90.56 | $207.65K | 102,929 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +1,642 | $85.01 | $139.59K | 100,636 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,623 | $83.58 | $219.23K | 98,994 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +3,023 | $83.20 | $251.51K | 96,371 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +1,643 | $80.50 | $132.26K | 93,348 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,864 | $77.67 | $222.45K | 91,705 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,623 | $74.78 | $196.15K | 88,841 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +2,072 | $71.93 | $149.04K | 76,759 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Option exercise | +9,459 | $72.27 | $683.60K | 86,218 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 31, 2026 | Sale(10b5-1 plan) | −4,695 | $119.39 | $560.54K | 70,294 |
| Richard A. Hoffman EVP & General Counsel | Jul 16, 2026 | Award | +7,395 | – | – | 16,861 |
| Ramitpal K. Basi EVP, Human Resources | Jul 16, 2026 | Award | +4,991 | – | – | 11,497 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Jul 16, 2026 | Award | +9,798 | – | – | 30,916 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Jul 16, 2026 | Sale(10b5-1 plan) | −1,877 | $114.73 | $215.35K | 21,118 |
| Pablo J. Cagnoni President, Global Head of R&D | Jul 16, 2026 | Award | +13,403 | – | – | 231,332 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 16, 2026 | Award | +5,916 | – | – | 63,628 |
| Mohamed Khairie Issa EVP, Head of U.S. Commercial | Jul 16, 2026 | Sale(10b5-1 plan) | −1,093 | $115.01 | $125.71K | 63,940 |
| Mohamed Khairie Issa EVP, Head of U.S. Commercial | Jul 16, 2026 | Award | +7,857 | – | – | 71,797 |
| William Meury Chief Executive Officer, Director | Jul 16, 2026 | Award | +26,807 | – | – | 183,129 |
| David H. Gardner EVP, Chief Strategy Officer | Jul 16, 2026 | Award | +7,395 | – | – | 16,824 |
| Thomas Tray Principal Accounting Officer | Jul 16, 2026 | Award | +2,834 | – | – | 21,699 |
| Mohamed Khairie Issa EVP, Head of U.S. Commercial | Jul 15, 2026 | Tax withholding | −1,099 | $115.09 | $126.48K | 65,033 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 15, 2026 | Tax withholding | −1,512 | $115.09 | $174.02K | 57,712 |
| Thomas Tray Principal Accounting Officer | Jul 15, 2026 | Tax withholding | −1,098 | $115.09 | $126.37K | 18,865 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Jul 15, 2026 | Sale(10b5-1 plan) | −28,237 | $113.05 | $3.19M | 26,083 |
| Steven H. Stein CMO & Head of Late-Stage Dev. | Jul 15, 2026 | Tax withholding | −3,088 | $115.09 | $355.40K | 22,995 |
| Pablo J. Cagnoni President, Global Head of R&D | Jul 15, 2026 | Tax withholding | −4,950 | $115.09 | $569.70K | 217,929 |
| Patrick A. Mayes EVP & Chief Scientific Officer | Jul 14, 2026 | Tax withholding | −437 | $114.88 | $50.20K | 59,224 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Cagnoni Pablo Officer | Sep 15, 2026 | 23,218 | $2.80M | Sep 15, 2026 | Stock Option Exercise |
| Cagnoni Pablo Officer | Aug 19, 2026 | 10,801 | $1.36M | Aug 19, 2026 | Restricted Stock and Performance Shares |
| Cagnoni Pablo Officer | Aug 12, 2026 | 10,803 | $1.30M | Aug 12, 2026 | Performance and Restricted Stock |
| Cagnoni Pablo Officer | Aug 5, 2026 | 10,640 | $1.31M | Aug 5, 2026 | Restricted Stock and Performance Shares |
| A. Mayes Patrick Officer | Aug 5, 2026 | 2,207 | $273.65K | Aug 5, 2026 | Stock Option Exercise |
| A. Mayes Patrick Officer | Aug 3, 2026 | 6,055 | $729.20K | Aug 3, 2026 | Stock Option Exercise |
| A. Mayes Patrick Officer | Jul 31, 2026 | 41,899 | $5.01M | Jul 31, 2026 | Stock Option Exercise |
| Cagnoni Pablo Officer | Jul 31, 2026 | 15,888 | $1.90M | Jul 31, 2026 | Restricted Stock |
| Issa Mohamed Officer | Jul 16, 2026 | 1,093 | $125.71K | Jul 16, 2026 | Restricted Stock |
| Stein Steven Officer | Jul 16, 2026 | 1,877 | $215.34K | Jul 16, 2026 | Restricted Stock |
| Stein Steven Officer | Jul 15, 2026 | 28,237 | $3.19M | Jul 15, 2026 | Performance Shares |
| R. Tray Thomas Officer | Jun 4, 2026 | 2,639 | $263.90K | Jun 4, 2026 | Stock Option Exercise |
| R. Tray Thomas Officer | May 26, 2026 | 2,051 | $199.66K | May 26, 2026 | Restricted Stock |
| J. Clancy Paul Director | May 19, 2026 | 15,000 | $1.42M | May 19, 2026 | Stock Option Exercise |
| Cagnoni Pablo Officer | Apr 17, 2026 | 18,667 | $1.80M | Apr 17, 2026 | Stock Option Exercise |